Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2017

Open Access 01-12-2017 | Research

Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report

Authors: Toni Seppälä, Kirsi Pylvänäinen, Dafydd Gareth Evans, Heikki Järvinen, Laura Renkonen-Sinisalo, Inge Bernstein, Elke Holinski-Feder, Paola Sala, Annika Lindblom, Finlay Macrae, Ignacio Blanco, Rolf Sijmons, Jacqueline Jeffries, Hans Vasen, John Burn, Sigve Nakken, Eivind Hovig, Einar Andreas Rødland, Kukatharmini Tharmaratnam, Wouter H. de Vos tot Nederveen Cappel, James Hill, Juul Wijnen, Mark Jenkins, Maurizio Genuardi, Kate Green, Fiona Lalloo, Lone Sunde, Miriam Mints, Lucio Bertario, Marta Pineda, Matilde Navarro, Monika Morak, Ian M. Frayling, John-Paul Plazzer, Julian R. Sampson, Gabriel Capella, Gabriela Möslein, Jukka-Pekka Mecklin, Pål Møller, in collaboration with The Mallorca Group

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2017

Login to get access

Abstract

Background

We have previously reported a high incidence of colorectal cancer (CRC) in carriers of pathogenic MLH1 variants (path_MLH1) despite follow-up with colonoscopy including polypectomy.

Methods

The cohort included Finnish carriers enrolled in 3-yearly colonoscopy (n = 505; 4625 observation years) and carriers from other countries enrolled in colonoscopy 2-yearly or more frequently (n = 439; 3299 observation years). We examined whether the longer interval between colonoscopies in Finland could explain the high incidence of CRC and whether disease expression correlated with differences in population CRC incidence.

Results

Cumulative CRC incidences in carriers of path_MLH1 at 70-years of age were 41% for males and 36% for females in the Finnish series and 58% and 55% in the non-Finnish series, respectively (p > 0.05). Mean time from last colonoscopy to CRC was 32.7 months in the Finnish compared to 31.0 months in the non-Finnish (p > 0.05) and was therefore unaffected by the recommended colonoscopy interval. Differences in population incidence of CRC could not explain the lower point estimates for CRC in the Finnish series. Ten-year overall survival after CRC was similar for the Finnish and non-Finnish series (88% and 91%, respectively; p > 0.05).

Conclusions

The hypothesis that the high incidence of CRC in path_MLH1 carriers was caused by a higher incidence in the Finnish series was not valid. We discuss whether the results were influenced by methodological shortcomings in our study or whether the assumption that a shorter interval between colonoscopies leads to a lower CRC incidence may be wrong. This second possibility is intriguing, because it suggests the dogma that CRC in path_MLH1 carriers develops from polyps that can be detected at colonoscopy and removed to prevent CRC may be erroneous. In view of the excellent 10-year overall survival in the Finnish and non-Finnish series we remain strong advocates of current surveillance practices for those with LS pending studies that will inform new recommendations on the best surveillance interval.
Appendix
Available only for authorised users
Literature
1.
go back to reference Vasen HFA, Blanco I, Aktán-Collán K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.CrossRefPubMedPubMedCentral Vasen HFA, Blanco I, Aktán-Collán K, Gopie JP, Alonso A, Aretz S, et al. Revised guidelines for the clinical management of lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. 2013;62:812–23.CrossRefPubMedPubMedCentral
2.
go back to reference Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective lynch syndrome database. Gut. 2017;66:464–72.CrossRefPubMed Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, et al. Cancer incidence and survival in lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective lynch syndrome database. Gut. 2017;66:464–72.CrossRefPubMed
3.
go back to reference Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.CrossRefPubMed Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34.CrossRefPubMed
4.
go back to reference Mecklin J-P, Aarnio M, Läärä E, Kairaluoma MV, Pylvänäinen K, Peltomäki P, et al. Development of colorectal tumors in colonoscopic surveillance in lynch syndrome. Gastroenterology. 2007;133:1093–8.CrossRefPubMed Mecklin J-P, Aarnio M, Läärä E, Kairaluoma MV, Pylvänäinen K, Peltomäki P, et al. Development of colorectal tumors in colonoscopic surveillance in lynch syndrome. Gastroenterology. 2007;133:1093–8.CrossRefPubMed
5.
go back to reference Stormorken AT, Clark N, Grindedal E, Mæhle L, Møller P. Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. Scand J Gastroenterol. 2007;42:611–7.CrossRefPubMed Stormorken AT, Clark N, Grindedal E, Mæhle L, Møller P. Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer. Scand J Gastroenterol. 2007;42:611–7.CrossRefPubMed
6.
go back to reference Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with lynch syndrome. Color Dis. 2015;17:38–46.CrossRef Newton K, Green K, Lalloo F, Evans DG, Hill J. Colonoscopy screening compliance and outcomes in patients with lynch syndrome. Color Dis. 2015;17:38–46.CrossRef
7.
go back to reference Vasen HFA, Abdirahman M, Brohet R, Langers AMJ, Kleibeuker JH, van Kouwen M, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with lynch syndrome. Gastroenterology. 2010;138:2300–6.CrossRefPubMed Vasen HFA, Abdirahman M, Brohet R, Langers AMJ, Kleibeuker JH, van Kouwen M, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with lynch syndrome. Gastroenterology. 2010;138:2300–6.CrossRefPubMed
8.
go back to reference Pylvänäinen K, Kairaluoma M, Mecklin J-P. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Familial Cancer. 2006;5:175–8.CrossRefPubMed Pylvänäinen K, Kairaluoma M, Mecklin J-P. Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Familial Cancer. 2006;5:175–8.CrossRefPubMed
9.
go back to reference Olsen KR, Bojesen SE, Gerdes A-MM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care. 2007;23:89–95.CrossRefPubMed Olsen KR, Bojesen SE, Gerdes A-MM, Lindorff-Larsen K, Bernstein IT. Cost-effectiveness of surveillance programs for families at high and moderate risk of hereditary non-polyposis colorectal cancer. Int J Technol Assess Health Care. 2007;23:89–95.CrossRefPubMed
10.
go back to reference Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol. 2004;22:4486–94.CrossRefPubMed Plaschke J, Engel C, Krüger S, Holinski-Feder E, Pagenstecher C, Mangold E, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German hereditary nonpolyposis colorectal cancer consortium. J Clin Oncol. 2004;22:4486–94.CrossRefPubMed
11.
go back to reference Bertario L, Russo A, Sala P, Eboli M, Radice P, Presciuttini S, et al. Survival of patients with hereditary colorectal cancer: comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer. Int J Cancer. 1999;80:183–7.CrossRefPubMed Bertario L, Russo A, Sala P, Eboli M, Radice P, Presciuttini S, et al. Survival of patients with hereditary colorectal cancer: comparison of HNPCC and colorectal cancer in FAP patients with sporadic colorectal cancer. Int J Cancer. 1999;80:183–7.CrossRefPubMed
12.
go back to reference Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (lynch syndrome). Lancet. 1995;345:1183–4.CrossRefPubMed Vasen HF, Nagengast FM, Khan PM. Interval cancers in hereditary non-polyposis colorectal cancer (lynch syndrome). Lancet. 1995;345:1183–4.CrossRefPubMed
13.
go back to reference Dove-Edwin I, Sasieni P, Adams J, Thomas HJW. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331:1047.CrossRefPubMedPubMedCentral Dove-Edwin I, Sasieni P, Adams J, Thomas HJW. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005;331:1047.CrossRefPubMedPubMedCentral
14.
go back to reference Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomäki P, Aaltonen LA, Mecklin J-P. Ten years after mutation testing for lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27:4793–7.CrossRefPubMed Järvinen HJ, Renkonen-Sinisalo L, Aktán-Collán K, Peltomäki P, Aaltonen LA, Mecklin J-P. Ten years after mutation testing for lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27:4793–7.CrossRefPubMed
15.
go back to reference de Vos Tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon rectum. 2002;45:1588–94.CrossRefPubMed de Vos Tot Nederveen Cappel WH, Nagengast FM, Griffioen G, Menko FH, Taal BG, Kleibeuker JH, et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon rectum. 2002;45:1588–94.CrossRefPubMed
16.
go back to reference Stupart DA, Goldberg PA, Algar U, Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Color Dis. 2009;11:126–30.CrossRef Stupart DA, Goldberg PA, Algar U, Ramesar R. Surveillance colonoscopy improves survival in a cohort of subjects with a single mismatch repair gene mutation. Color Dis. 2009;11:126–30.CrossRef
17.
go back to reference Engel C, Rahner N, Schulmann K, Feder EH, Goecke TO, Schackert HK, et al. Efficacy of annual Colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. YJCGH. 2010;8:174–82. Engel C, Rahner N, Schulmann K, Feder EH, Goecke TO, Schackert HK, et al. Efficacy of annual Colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. YJCGH. 2010;8:174–82.
18.
go back to reference Stuckless S, Green JS, Morgenstern M, Kennedy C, Green RC, Woods MO, et al. Impact of colonoscopic screening in male and female lynch syndrome carriers with an MSH2 mutation. Clin Genet. 2012;82:439–45.CrossRefPubMed Stuckless S, Green JS, Morgenstern M, Kennedy C, Green RC, Woods MO, et al. Impact of colonoscopic screening in male and female lynch syndrome carriers with an MSH2 mutation. Clin Genet. 2012;82:439–45.CrossRefPubMed
19.
go back to reference Thompson BA, Spurdle AB, Plazzer J-P, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2014;46:107–15.CrossRefPubMed Thompson BA, Spurdle AB, Plazzer J-P, Greenblatt MS, Akagi K, Al-Mulla F, et al. Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet. 2014;46:107–15.CrossRefPubMed
20.
go back to reference Mesher D, Dove-Edwin I, Sasieni P, Vasen H, Bernstein I, Royer-Pokora B, et al. A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. Int J Cancer. 2014;134:939–47.CrossRefPubMed Mesher D, Dove-Edwin I, Sasieni P, Vasen H, Bernstein I, Royer-Pokora B, et al. A pooled analysis of the outcome of prospective colonoscopic surveillance for familial colorectal cancer. Int J Cancer. 2014;134:939–47.CrossRefPubMed
21.
go back to reference Kloor M, Huth C, Voigt AY, Benner A, Schirmacher P, Knebel-Doeberitz von M, et al. Prevalence of mismatch repair-deficient crypt foci in lynch syndrome: a pathological study. Lancet Oncol. 2012;13:598–606.CrossRefPubMed Kloor M, Huth C, Voigt AY, Benner A, Schirmacher P, Knebel-Doeberitz von M, et al. Prevalence of mismatch repair-deficient crypt foci in lynch syndrome: a pathological study. Lancet Oncol. 2012;13:598–606.CrossRefPubMed
22.
go back to reference Kloor M, Michel S, Buckowitz B, Rüschoff J, Büttner R, Holinski-Feder E, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer. 2007;121:454–8.CrossRefPubMed Kloor M, Michel S, Buckowitz B, Rüschoff J, Büttner R, Holinski-Feder E, et al. Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer. 2007;121:454–8.CrossRefPubMed
23.
go back to reference Ahadova A, Knebel-Doeberitz von M, Bläker H, Kloor M. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in lynch syndrome. Familial Cancer. 2016;15:579–86.CrossRefPubMed Ahadova A, Knebel-Doeberitz von M, Bläker H, Kloor M. CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in lynch syndrome. Familial Cancer. 2016;15:579–86.CrossRefPubMed
24.
go back to reference de Jong AE, Morreau H, Van Puijenbroek M, Eilers PHC, Wijnen J, Nagengast FM, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology. 2004;126:42–8.CrossRefPubMed de Jong AE, Morreau H, Van Puijenbroek M, Eilers PHC, Wijnen J, Nagengast FM, et al. The role of mismatch repair gene defects in the development of adenomas in patients with HNPCC. Gastroenterology. 2004;126:42–8.CrossRefPubMed
25.
go back to reference Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut. 2002;50:228–34.CrossRefPubMedPubMedCentral Lindgren G, Liljegren A, Jaramillo E, Rubio C, Lindblom A. Adenoma prevalence and cancer risk in familial non-polyposis colorectal cancer. Gut. 2002;50:228–34.CrossRefPubMedPubMedCentral
26.
go back to reference Forsberg A, Kjellström L, Andreasson A, Jaramillo E, Rubio CA, Björck E, et al. Colonoscopy findings in high-risk individuals compared to an average-risk control population. Scand J Gastroenterol. 2015;50:1–9.CrossRef Forsberg A, Kjellström L, Andreasson A, Jaramillo E, Rubio CA, Björck E, et al. Colonoscopy findings in high-risk individuals compared to an average-risk control population. Scand J Gastroenterol. 2015;50:1–9.CrossRef
Metadata
Title
Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report
Authors
Toni Seppälä
Kirsi Pylvänäinen
Dafydd Gareth Evans
Heikki Järvinen
Laura Renkonen-Sinisalo
Inge Bernstein
Elke Holinski-Feder
Paola Sala
Annika Lindblom
Finlay Macrae
Ignacio Blanco
Rolf Sijmons
Jacqueline Jeffries
Hans Vasen
John Burn
Sigve Nakken
Eivind Hovig
Einar Andreas Rødland
Kukatharmini Tharmaratnam
Wouter H. de Vos tot Nederveen Cappel
James Hill
Juul Wijnen
Mark Jenkins
Maurizio Genuardi
Kate Green
Fiona Lalloo
Lone Sunde
Miriam Mints
Lucio Bertario
Marta Pineda
Matilde Navarro
Monika Morak
Ian M. Frayling
John-Paul Plazzer
Julian R. Sampson
Gabriel Capella
Gabriela Möslein
Jukka-Pekka Mecklin
Pål Møller
in collaboration with The Mallorca Group
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2017
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-017-0078-5

Other articles of this Issue 1/2017

Hereditary Cancer in Clinical Practice 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine